Announcement on Completing Industrial and Commercial Change Registration
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Completing Industrial and Commercial Change Registration
Filed with SSE ·
6ix hasn’t read this filing yet.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix
Earlier from Nanjing King-friend Biochemical Pharmaceutical
- Indicative Announcement on the Proposed Reversal of Inventory Impairment
- Announcement on Not Revising Downward Conversion Price of ""King-friend Convertible Bonds"
- Indicative Announcement on the Expected Fulfillment of Conversion Price Amendment Conditions for ""King-Friend Convertible Bonds"
- Announcement on Obtaining FDA Approval by Subsidiary for Propofol Injectable Emulsion
- Announcement on Approval of Subsidiary's Product Dalbavancin for Injection by the U.S. FDA
Later from Nanjing King-friend Biochemical Pharmaceutical
- Announcement on Obtaining FDA Approval by Subsidiary for Sodium Selenite Injection
- Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Lafamulin Injection from FDA of the United States
- The 1st Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
- The 2nd Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
- The 3rd Indicative Announcement on Maturity and Redemption of "King-Friend Convertible Bonds" and Delisting
Follow Nanjing King-friend Biochemical Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing King-friend Biochemical Pharmaceutical